Foamix, a Rehovot-based firm that helps develop foam and gel-based pharmaceuticals, reportedly filed a confidential prospectus last week in advance of plans to list on the Nasdaq.
The company was founded in 2003 by Dov Tamarkin, a former senior executive at Teva Pharmaceutical Industries, and his partner Meir Eini.
It develops topical products for treating skin diseases and gynecological conditions. The company has a staff of 20, most of whom do research and development.
Although the company’s founders deny having filed a prospectus, they said last week they were making the rounds among underwriters over a offering. Confidential prospectuses are sometimes used by companies to help gauge investor interest.